← Back to headlines
H.C. Wainwright Maintains Buy Rating on Iovance Biotherapeutics
H.C. Wainwright has reiterated its "Buy" rating on Iovance Biotherapeutics (IOVA), indicating continued confidence in the company's stock.
16 Jun, 18:46 — 16 Jun, 18:46
Sources
Showing 1 of 1 sources
Related Stories
Signet Jewelers Raises Profit Forecast After Strong Quarterly Results
45m ago
Nigeria’s Oil Regulator Threatens Permit Revocations for Idle Gas Flare Sites
1h ago
Record Travel Demand Hits Dublin Airport and Portuguese Cruise Industry
1h ago
Corporate Earnings Highlights from Wells Fargo and Goldman Sachs Conferences
1h ago